2020
15 January, 2020
Excellent result of FluoGuide’s FG001 guiding surgical removal of cancer is published
The study aimed at investigating the resection of the human pancreatic cancer using an orthotopic xenograft pancreatic cancer model...
9 January, 2020
Safety study initiated with FG001
FluoGuide’s FG001 is designed to be well tolerated and its two main components have both demonstrated excellent tolerability...
FluoGuide’s first product FG001 lights up the cancer and its invasive growth into the surrounding tissue. FG001 is expected to...
2019
29 November, 2019
Interim Report Third Quarter 2019
Morten Albrechtsen, CEO of FluoGuide, comments: “We are very pleased that the supply chain for FG001 has been established to...
25 November, 2019
FluoGuide presentation at Sedermeradagen in Stockholm and Investordagen in Aalborg
At Sedermeradagen in Stockholm, Morten Albrechtsen, CEO and Andreas Kjaer, CSO presented in front of approx. 300 investors. The presentation...
25 November, 2019
FluoGuide A/S: Change of report date
30 November is a Saturday and the report date is therefore changed to Friday, 29 November 2019. For further information, please contact...
20 September, 2019
Presentation of FluoGuide at Life Science Investorkonference Q3 2019
FluoGuide A/S ("FluoGuide", ticker FLUO) was presented at the 18 September at the Life Science Investorkonference in Copenhagen...
7 September, 2019
Presentation of data where FG001 demonstrates dose-depended effectiveness in lightening up glioblastoma in a preclinical model
Despite several decades of effort in improving the standard therapy of Glioblastoma (GBM), an aggressive form of cancer in the brain...
6 September, 2019
Presentation of data where use of FG001 demonstrates improved surgical outcome in metastatic pancreatic cancer compared to standard surgery using only white light
Pancreatic cancer remains one of the deadliest cancers, and the one and five-year survival rates have been reported as 15% and 3% (Carrato...